Literature DB >> 29184046

Decoding resistant hypertension signalling pathways.

Ricardo Cambraia Parreira1,2, Leandro Heleno Guimarães Lacerda3, Rebecca Vasconcellos1,2, Swiany Silveira Lima1, Anderson Kenedy Santos1, Vanessa Fontana4, Valéria Cristina Sandrim5, Rodrigo Ribeiro Resende6,2.   

Abstract

Resistant hypertension (RH) is a clinical condition in which the hypertensive patient has become resistant to drug therapy and is often associated with increased cardiovascular morbidity and mortality. Several signalling pathways have been studied and related to the development and progression of RH: modulation of sympathetic activity by leptin and aldosterone, primary aldosteronism, arterial stiffness, endothelial dysfunction and variations in the renin-angiotensin-aldosterone system (RAAS). miRNAs comprise a family of small non-coding RNAs that participate in the regulation of gene expression at post-transcriptional level. miRNAs are involved in the development of both cardiovascular damage and hypertension. Little is known of the molecular mechanisms that lead to development and progression of this condition. This review aims to cover the potential roles of miRNAs in the mechanisms associated with the development and consequences of RH, and explore the current state of the art of diagnostic and therapeutic tools based on miRNA approaches.
© 2017 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society.

Entities:  

Keywords:  Signaling Pathways; microRNA; resistant hypertension

Mesh:

Substances:

Year:  2017        PMID: 29184046     DOI: 10.1042/CS20171398

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  5 in total

Review 1.  Potential Strategies to Reduce Blood Pressure in Treatment-Resistant Hypertension Using Food and Drug Administration-Approved Nanodrug Delivery Platforms.

Authors:  Ibra S Fancher; Israel Rubinstein; Irena Levitan
Journal:  Hypertension       Date:  2019-02       Impact factor: 10.190

2.  Transcriptomic Profiling Reveals Underlying Immunoregulation Mechanisms of Resistant Hypertension in Injection Drug Users.

Authors:  Jie Jia; Ji-Qun Yang; Ying-Rong Du; Yu Xu; Deshenyue Kong; Xiu-Ling Zhang; Jun-Hong Mao; Gui-Fang Hu; Kun-Hua Wang; Yi-Qun Kuang
Journal:  J Inflamm Res       Date:  2022-06-09

3.  Aldosterone-induced microRNAs act as feedback regulators of mineralocorticoid receptor signaling in kidney epithelia.

Authors:  Nejla Ozbaki-Yagan; Xiaoning Liu; Andrew J Bodnar; Jacqueline Ho; Michael Bruce Butterworth
Journal:  FASEB J       Date:  2020-07-11       Impact factor: 5.191

Review 4.  Non-coding RNAs and the mineralocorticoid receptor in the kidney.

Authors:  Michael B Butterworth
Journal:  Mol Cell Endocrinol       Date:  2020-12-07       Impact factor: 4.102

5.  MicroRNA 21 and microRNA 155 levels in resistant hypertension, and their relationships with aldosterone.

Authors:  Sonat Pınar Kara; Gulsum Ozkan; Ahsen Yılmaz; Nergiz Bayrakçı; Savaş Güzel; Elif Geyik
Journal:  Ren Fail       Date:  2021-12       Impact factor: 2.606

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.